DUGi

Darrers avenços en el desenvolupament de fàrmacs biotecnològics multi-domini

http://dugi.udg.edu/item/http:@@@@hdl.handle.net@@10256@@28556

Given the growing interest in multi-domain biotechnological drugs due to their potential to improve the pharmacokinetic and pharmacodynamic properties of conventional protein drugs, this literature review aims to provide a detailed or comprehensive description of the most recent advances in the development of these drugs. First, it describes what fusion proteins, multi-domain drugs, pharmacokinetics and pharmacodynamics are, mentioning the properties that these drugs can improve. Next, it describes the functional domains that can form part of these molecules, such as domains that allow them to cross physiological barriers, protein transduction domains, and receptor-binding domains, among others, explaining the function of each and the mechanisms by which they exert their therapeutic action. This paper also reviews the most relevant studies in this field, as well as the current and potential therapeutic applications of these drugs in pathologies such as cancer and neurodegenerative disorders such as Alzheimer. Finally, the main limitations facing these types of therapies are analysed, including structural stability, immunogenicity and complexity in their production. This analysis allows us to assess the emerging role of multi-domain drugs in biomedical innovation and their future prospects in the design of more effective and personalised therapies

3